Spark Therapeutics has accepted a tender offer for all outstanding shares of common stock at a price of $114.50 per share, allowing Roche to complete its acquisition of the company, according to a press release.
The deal, which was announced in February 2019, cleared all regulatory hurdles Monday when it was approved by the U.K. Competition and Markets Authority and the U.S. Federal Trade Commission.
“We are excited about this important milestone because we believe that together, Roche and Spark will be able to significantly improve the lives of patients (Read more...)
Uncategorized